Natco Pharma soars on getting USFDA's tentative approval for Olaparib tablets
Natco Pharma is currently trading at Rs. 967.10, up by 21.35 points or 2.26% from its previous closing of Rs. 945.75 on the BSE.
The scrip opened at Rs. 960.20 and has touched a high and low of Rs. 986.00 and Rs. 960.00 respectively. So far 91657 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 1226.10 on 12-May-2026 and a 52 week low of Rs. 789.30 on 30-Sep-2025.
Last one week high and low of the scrip stood at Rs. 989.75 and Rs. 941.65 respectively. The current market cap of the company is Rs. 16939.32 crore.
The promoters holding in the company stood at 49.42%, while Institutions and Non-Institutions held 22.60% and 27.98% respectively.
Natco Pharma has received tentative approval from the United States Food and Drug Administration (USFDA) for Olaparib, 100 mg, and 150 mg, as bioequivalent to reference listed drug (RLD) Lynparza tablets of AstraZeneca Pharmaceuticals for the indication in the approved labelling. NATCO will be manufacturing Olaparib tablets and its partner Alembic Pharmaceuticals (Alembic), would be distributing the product in the U.S.
The Para IV litigation is on-going. Olaparib tablets had estimated sales of around $1.4 billion in the U.S. for 12 months ending March 2026 as per industry sales data.
Natco Pharma is a vertically integrated and R&D focused pharmaceutical company engaged in developing, manufacturing and marketing of Finished Dosage Formulations (FDF) and Active Pharmaceutical Ingredients (APIs).
